Oncology Platform Support for Routine Care

University of Glasgow spinout company Gabriel Precision Oncology Ltd is collaborating with digital health company Congenica, to develop a highly automated somatic cancer clinical interpretation platform, supporting the use of multiple genomic assays in routine clinical practice.

Developed by Professor Andrew Biankin’s team at Glasgow for detection of genomic variants relevant for cancer, the software pipeline has been optimised to produce high quality data from formalin exposed DNA sequencing.

Gabriel was founded by Professor Andrew Biankin, Dr Susanna Cooke and Dr Philip Beer, who between them have deep expertise and experience in cancer genomics and therapeutic development and have played influential roles in national and international genomics consortia.

Freddie Sharkey, PhD, VP Oncology & EMEA Sales, said: “This collaboration signifies the expansion of Congenica’s product platform into somatic cancer, a disease area which we believe can significantly benefit from our platform. Gabriel brings together extensive international genomics expertise and its platform has been developed specifically to work with tumour derived DNA. We look forward to working with Gabriel to further incorporate clinical genomics into routine cancer care.”

Andrew Biankin, University of Glasgow and Gabriel, said: “Still too few people have access to advanced molecular cancer diagnostics and as a consequence miss out on potential treatments and clinical trials. A distributed model where laboratories and health systems around the world can do their own tests for their own patients using a standardised and comparable analytical platform will enable more patients to access precision medicine. Congenica’s technology is market-leading in terms of the rapid interpretation of genomic data and working together we believe that our platform will enable many more cancer patients to access new treatments.”